Literature DB >> 25246622

Favorable outcome after physiologic dose of sodium-D,L-3-hydroxybutyrate in severe MADD.

Willemijn J Van Rijt1, M Rebecca Heiner-Fokkema2, Gideon J du Marchie Sarvaas3, Hans R Waterham4, Robert G T Blokpoel5, Francjan J van Spronsen1, Terry G J Derks6.   

Abstract

Multiple acyl coenzyme A dehydrogenase deficiency (MADD) is a severe inborn error of metabolism. Experiences with sodium-D,L-3-hydroxybutyrate (3-HB) treatment are limited although positive; however, the general view on outcome of severely affected patients with MADD is relatively pessimistic. Here we present an infant with MADD in whom the previously reported dose of 3-HB did not prevent the acute, severe, metabolic decompensation or progressive cardiomyopathy in the subsequent months. Only after a physiologic dose of 2600 mg/kg of 3-HB per day were ketone bodies detected in blood associated with improvement of the clinical course, N-terminal prohormone of brain natriuretic peptide and echocardiographic parameters. Long-term studies are warranted on 3-HB treatment in patients with MADD.
Copyright © 2014 by the American Academy of Pediatrics.

Entities:  

Keywords:  cardiomyopathy; mitochondrial fatty acid oxidation; multiple acyl coenzyme A dehydrogenase deficiency; sodium-d,l-3-hydroxybutyrate

Mesh:

Substances:

Year:  2014        PMID: 25246622     DOI: 10.1542/peds.2013-4254

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  6 in total

1.  Targeted Therapies for Metabolic Myopathies Related to Glycogen Storage and Lipid Metabolism: a Systematic Review and Steps Towards a 'Treatabolome'.

Authors:  A Manta; S Spendiff; H Lochmüller; R Thompson
Journal:  J Neuromuscul Dis       Date:  2021

2.  Effect of a Sodium and Calcium DL-β-Hydroxybutyrate Salt in Healthy Adults.

Authors:  Tobias Fischer; Ulrike Och; Ira Klawon; Tim Och; Marianne Grüneberg; Manfred Fobker; Ursula Bordewick-Dell; Thorsten Marquardt
Journal:  J Nutr Metab       Date:  2018-04-12

3.  Glutaric acidemia type II patient with thalassemia minor and novel electron transfer flavoprotein-A gene mutations: A case report and review of literature.

Authors:  Neslihan Yildirim Saral; Fehime Benli Aksungar; Cigdem Aktuglu-Zeybek; Julide Coskun; Ozlem Demirelce; Mustafa Serteser
Journal:  World J Clin Cases       Date:  2018-11-26       Impact factor: 1.337

4.  Ketone body therapy with D/L-β-hydroxybutyric acid solution in severe MADD.

Authors:  Tobias Fischer; Christiane Elpers; Ulrike Och; Manfred Fobker; Thorsten Marquardt
Journal:  Mol Genet Metab Rep       Date:  2019-06-28

Review 5.  Cardiac Complications of Propionic and Other Inherited Organic Acidemias.

Authors:  Kyung Chan Park; Steve Krywawych; Eva Richard; Lourdes R Desviat; Pawel Swietach
Journal:  Front Cardiovasc Med       Date:  2020-12-22

6.  Efficacy and safety of D,L-3-hydroxybutyrate (D,L-3-HB) treatment in multiple acyl-CoA dehydrogenase deficiency.

Authors:  Willemijn J van Rijt; Emmalie A Jager; Derk P Allersma; A Çiğdem Aktuğlu Zeybek; Kaustuv Bhattacharya; François-Guillaume Debray; Carolyn J Ellaway; Matthias Gautschi; Michael T Geraghty; David Gil-Ortega; Austin A Larson; Francesca Moore; Eva Morava; Andrew A Morris; Kimihiko Oishi; Manuel Schiff; Sabine Scholl-Bürgi; Michel C Tchan; Jerry Vockley; Peter Witters; Saskia B Wortmann; Francjan van Spronsen; Johan L K Van Hove; Terry G J Derks
Journal:  Genet Med       Date:  2020-01-06       Impact factor: 8.822

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.